Immunocore Holdings PLC logo

Immunocore Holdings PLC - ADR

1
NAS:IMCR (UK)   ADR
$ 46.05 -1.93 (-4.02%) 10:08 PM EST
At Loss
P/B:
5.07
Volume:
5.01M
Avg Vol (2M):
628.28K
Also Trade In:
Volume:
5.01M
At Loss
Avg Vol (2M):
628.28K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Immunocore Holdings PLC ( ) from 2021 to May 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Immunocore PLC stock (IMCR) PE ratio as of May 27 2024 is 0. More Details

Immunocore Holdings PLC (IMCR) PE Ratio (TTM) Chart

To

Immunocore Holdings PLC (IMCR) PE Ratio (TTM) Historical Data

Total 832
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10
Immunocore PLC PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-27 At Loss 2024-03-22 At Loss
2024-05-24 At Loss 2024-03-21 At Loss
2024-05-23 At Loss 2024-03-20 At Loss
2024-05-22 At Loss 2024-03-19 At Loss
2024-05-21 At Loss 2024-03-18 At Loss
2024-05-20 At Loss 2024-03-15 At Loss
2024-05-17 At Loss 2024-03-14 At Loss
2024-05-16 At Loss 2024-03-13 At Loss
2024-05-15 At Loss 2024-03-12 At Loss
2024-05-14 At Loss 2024-03-11 At Loss
2024-05-13 At Loss 2024-03-08 At Loss
2024-05-10 At Loss 2024-03-07 At Loss
2024-05-09 At Loss 2024-03-06 At Loss
2024-05-08 At Loss 2024-03-05 At Loss
2024-05-07 At Loss 2024-03-04 At Loss
2024-05-06 At Loss 2024-03-01 At Loss
2024-05-03 At Loss 2024-02-29 At Loss
2024-05-02 At Loss 2024-02-28 At Loss
2024-05-01 At Loss 2024-02-27 At Loss
2024-04-30 At Loss 2024-02-26 At Loss
2024-04-29 At Loss 2024-02-23 At Loss
2024-04-26 At Loss 2024-02-22 At Loss
2024-04-25 At Loss 2024-02-21 At Loss
2024-04-24 At Loss 2024-02-20 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-04-01 At Loss 2024-01-25 At Loss
2024-03-28 At Loss 2024-01-24 At Loss
2024-03-27 At Loss 2024-01-23 At Loss
2024-03-26 At Loss 2024-01-22 At Loss
2024-03-25 At Loss 2024-01-19 At Loss

Immunocore Holdings PLC (IMCR) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.